202 related articles for article (PubMed ID: 21193997)
1. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
3. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.
Lin WH; Yeh SH; Yang WJ; Yeh KH; Fujiwara T; Nii A; Chang SS; Chen PJ
Int J Cancer; 2013 Mar; 132(6):1451-62. PubMed ID: 22886913
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
5. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
[TBL] [Abstract][Full Text] [Related]
6. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
8. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
9. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
[TBL] [Abstract][Full Text] [Related]
10. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
11. Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma.
Lin ZZ; Hu MC; Hsu C; Wu YM; Lu YS; Ho JA; Yeh SH; Chen PJ; Cheng AL
Cancer Lett; 2023 Mar; 556():216063. PubMed ID: 36669725
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Tanaka N
Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
[TBL] [Abstract][Full Text] [Related]
13. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
15. Telomerase-specific replication-selective virotherapy for human cancer.
Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
[TBL] [Abstract][Full Text] [Related]
16. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
17. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Urata Y; Tanaka N
Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
Fujiwara T; Urata Y; Tanaka N
Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]